Kepler Capital Markets Analysts Give Merck KGaA (MRK) a €115.00 Price Target

Kepler Capital Markets set a €115.00 ($135.29) price objective on Merck KGaA (FRA:MRK) in a research note published on Monday, November 6th. The brokerage currently has a buy rating on the healthcare company’s stock.

MRK has been the topic of several other reports. J P Morgan Chase & Co set a €100.00 ($117.65) price objective on shares of Merck KGaA and gave the company a neutral rating in a report on Friday, October 6th. Citigroup Inc. set a €123.00 ($144.71) price objective on shares of Merck KGaA and gave the company a buy rating in a report on Monday, September 25th. Goldman Sachs Group Inc set a €105.00 ($123.53) price objective on shares of Merck KGaA and gave the company a neutral rating in a report on Tuesday, September 19th. DZ Bank AG reissued a sell rating on shares of Merck KGaA in a report on Tuesday, July 18th. Finally, UBS AG set a €120.00 ($141.18) price target on shares of Merck KGaA and gave the stock a buy rating in a report on Monday, October 2nd. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of €108.76 ($127.96).

Shares of Merck KGaA (MRK) traded down €0.65 ($0.76) during midday trading on Monday, reaching €89.15 ($104.88). 541,451 shares of the company’s stock traded hands. Merck KGaA has a twelve month low of €88.73 ($104.39) and a twelve month high of €115.00 ($135.29).

TRADEMARK VIOLATION NOTICE: This news story was posted by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/kepler-capital-markets-reiterates-115-00-price-target-for-merck-kgaa-mrk/1761567.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.